Although anxiety disorders were classified as neurotic disorders and not systematically studied before DSM-III, researchers and clinicians have been searching for effective, safe agents to treat anxiety symptoms and disorders for over a century. In that time, barbiturates, benzodiazepines, and many classes of antidepressants have been used as anxiolytics, all with side effect profiles that made them less than optimal treatments for anxiety. The recognition of the role of GABA in anxiety disorders has led researchers to develop anxiolytics that target GABA. The long-sought-after class of anxiolytics that are both effective and safe may be found in the new research being conducted with agents that selectively target GABA receptors and their subtypes.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Clinical Psychiatry|
|Issue number||SUPPL. 3|
|State||Published - Apr 12 2003|
ASJC Scopus subject areas
- Psychiatry and Mental health